Pancragen 20mg
Synthetic pancreatic tetrapeptide (KEDW) studied in preclinical models for pancreatic cell differentiation and glucose regulation.
Mechanism
Proposed to interact directly with DNA and core histones to epigenetically modulate the transcription of pancreatic differentiation factors like Pdx1 and Pax6.
Dosing
The primary in-vivo reference amount identified in literature is 50 mcg daily derived from rhesus monkey studies, as human dosing remains unestablished.
Reconstitution
Reconstituting a 20 mg vial with 3.0 mL of bacteriostatic water yields a research concentration of approximately 6.67 mg/mL.
Storage
Store the unmixed lyophilized powder refrigerated and shielded from light, and maintain the reconstituted liquid at 2–8 °C without freezing.
Mix & measure Pancragen 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Pancragen 20mg
Vial strength → BAC water → target dose
Total doses in vial: 400.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Published Monkey Amount | 50 mcg per animal/day | 0.0075 mL (~0.75 units) |
| Reference Point A | 100 mcg | 0.015 mL (1.5 units) |
| Reference Point B | 200 mcg | 0.03 mL (3.0 units) |
| Reference Point C | 500 mcg | 0.075 mL (7.5 units) |
Reconstitution Steps
- 1
Sanitize the rubber stoppers of both the Pancragen vial and the bacteriostatic water vial using sterile alcohol swabs and allow them to air dry.
- 2
Verify the identity and purity of the synthetic KEDW peptide via a third-party certificate of analysis.
- 3
Draw 3.0 mL of bacteriostatic water using a sterile syringe and slowly introduce it down the inner wall of the peptide vial to avoid excessive agitation.
- 4
Allow the solution to rest undisturbed for 30 seconds, then roll the vial gently between the palms until the powder is fully dissolved without shaking.
- 5
Inspect the final solution to confirm clarity, ensuring it is free of cloudiness or particulate matter before refrigerating at 2–8 °C.
Supplies Needed
Peptide Vial
Lyophilized synthetic Pancragen (20 mg) for laboratory research
Insulin Syringes (U-100)
Calibrated syringes used for micro-volume liquid measurements and transfers
Bacteriostatic Water
Sterile diluent (3.0 mL) formulated with benzyl alcohol to reconstitute the peptide
Alcohol Swabs
Antiseptic pads utilized to disinfect vial tops and maintain an aseptic environment
Why researchers study it
Blood sugar & glucose control
Insulin & insulin resistance
Pancreatic cell function
Healthy aging
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Pancragen is a synthetic tetrapeptide consisting of Lys-Glu-Asp-Trp (KEDW) developed within the Russian bioregulator research paradigm. It was designed to mimic the regulatory properties of native pancreatic tissue extracts, targeting acinar and islet cells to modulate cellular differentiation and functional vitality. Preclinical research in cellular systems, diabetic rodent models, and non-human primates indicates that Pancragen promotes the expression of critical transcription factors such as Pdx1 and Pax6 while aiding systemic glycemic markers. However, the compound has not undergone formal clinical trial evaluation, lacks an approved clinical dosing framework, and is solely intended for controlled experimental investigations.
References
- 1.Korkushko et al., Bulletin of Experimental Biology and Medicine, 2011 — Prospects of using pancragen for correction of metabolic disorders in elderly people
- 2.Goncharova et al., Advances in Gerontology, 2015 — Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys
- 3.Goncharova et al., Advances in Gerontology, 2014 — Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys
- 4.Khavinson et al., Bulletin of Experimental Biology and Medicine, 2007 — Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus
- 5.Khavinson et al., Bulletin of Experimental Biology and Medicine, 2013 — Effects of pancragen on the differentiation of pancreatic cells during their ageing
- 6.Khavinson et al., Bulletin of Experimental Biology and Medicine, 2012 — Peptides tissue-specifically stimulate cell differentiation during their aging
- 7.Ashapkin et al., Biochemistry (Moscow), 2015 — Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells
- 8.Fedoreyeva et al., Biochemistry (Moscow), 2013 — Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides
- 9.Tarnovskaya et al., Bulletin of Experimental Biology and Medicine, 2014 — Study of interactions between DNA and tetrapeptides using methods of molecular mechanics
- 10.Khavinson et al., Bulletin of Experimental Biology and Medicine, 2016 — Short peptides regulate gene expression
- 11.Zakutskii et al., Advances in Gerontology, 2006 — Tissue-specific effect of synthetic peptide bioregulators in organotypic tissue culture in young and old rats
- 12.Khavinson et al., Stem Cell Reviews and Reports, 2020 — Peptide Regulation of Cell Differentiation
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.